they spent nearly a third to a half billion dollars. They bought the French RNA company Actigenics.
Cepheid Quietly Acquires microRNA Company Actigenics ...
August 09, 2006
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancerspecific markers, infection-specific markers, inflammation-specific markers, and surrogate markers of complex regulatory mechanisms,” the company said.